Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ORGANIZATION
ORGANIZATION
- April-June Generic Share at 54.4%: JGA
September 28, 2015
- Kenporen Proposal Prods Health Coverage Removal for “1st-Generation Poultices”
September 25, 2015
- JPMA Reprimands Pfizer over Failure to Report ADRs
September 18, 2015
- JPMA Helping Member Firms Expand into Emerging Asian Markets: Int’l Affairs Chief
September 17, 2015
- JPMA Policy Research Unit Sets Up Study Group on Big Data
September 10, 2015
- Drug Pricing Tomorrow: Full Interview with FPMAJ’s Kamoya - Part 2
September 8, 2015
- JPMA Chief Lauds MHLW’s Comprehensive Strategy, Says It Will Support Industry as a Whole
September 7, 2015
- JPMA to Start Educational Program for Biopharmaceutical Manufacturing Next Spring: Biopharmaceutical Chief
September 4, 2015
- Ryukaikon’s New Proposal “Will Greatly Promote the Improvement of Distribution”: JPWA President
September 2, 2015
- Cost-Effective Assessment Must Not Delay Patient Access: PhRMA’s HTA Chief
September 1, 2015
- JMA, JAMS Issue Guidelines for Dealing with Symptoms Following HPV Vaccination; Use of Word “Psychogenic” Should Be Avoided in Pain Diagnoses
August 21, 2015
- Compensation for Injured Subjects an “Agreement,” Not a “Benefit”: Ihoken Revised Guidelines
August 20, 2015
- Drug Pricing Tomorrow: Full Interview with FPMAJ’s Kamoya - Part 1
August 20, 2015
- Introduction of GDP Guideline Would Require Investment in Distribution Systems: JPMA Quality Chief
August 19, 2015
- Govt Leadership Needed to Promote Industry Reorganization, Strengthen Competitiveness: Former JPMA President Aoki
August 17, 2015
- Govt’s Policy Blueprint Will Lead to Soaring R&D Costs, More Early-Stage Projects: JPMA Drug Evaluation Chief
August 14, 2015
- Drug Pricing Tomorrow: Full Interview with JPA Executive Director Abe
August 13, 2015
- Drug Pricing Tomorrow: FPMAJ’s Kamoya Says Innovation Premium Meant to Head Off Future Drug Lags
August 10, 2015
- JPMA IP Committee Chair Predicts “Minimum Standard” for Data Protection Period for Drugs
August 5, 2015
- JPMA Establishes “Global Health Taskforce” in IP Committee
August 5, 2015
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…